Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Trimmed by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA decreased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 6.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,517,636 shares of the biopharmaceutical company’s stock after selling 110,241 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Amicus Therapeutics were worth $14,296,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. HealthInvest Partners AB grew its position in Amicus Therapeutics by 18.6% in the 4th quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock valued at $3,076,000 after buying an additional 51,368 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock worth $255,936,000 after acquiring an additional 2,856,101 shares during the period. Tempus Wealth Planning LLC bought a new position in shares of Amicus Therapeutics in the fourth quarter valued at approximately $259,000. Neo Ivy Capital Management acquired a new position in shares of Amicus Therapeutics during the third quarter valued at approximately $702,000. Finally, Intech Investment Management LLC lifted its position in Amicus Therapeutics by 59.7% in the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company’s stock worth $1,175,000 after purchasing an additional 46,633 shares during the period.

Amicus Therapeutics Price Performance

FOLD opened at $7.95 on Wednesday. Amicus Therapeutics, Inc. has a 12-month low of $7.88 and a 12-month high of $12.65. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $2.44 billion, a P/E ratio of -44.17, a PEG ratio of 1.51 and a beta of 0.69. The stock has a fifty day moving average of $9.22 and a 200-day moving average of $9.91.

Wall Street Analyst Weigh In

A number of research firms have recently commented on FOLD. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Wells Fargo & Company dropped their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.